New Genetic Test for Personalized Treatment of Breast Cancer

	Tweet

Researchers at Montefiore Medical Center are leading a nationwide clinical trial to determine whether a new genetic test can be used to personalize treatment for early-stage breast cancer.

“By using a molecular diagnostic test to assess whether a breast tumor will respond to chemotherapy, we’re hoping to more precisely identify which patients can be adequately treated with hormonal therapy alone and which patients will truly benefit if chemotherapy is added to the treatment,” said Joseph Sparano, MD, who directs the Breast Evaluation Center at the Montefiore-Einstein Cancer Center. “With better individualized treatment, we can spare women the side effects of chemotherapy where it is unnecessary.”

Dr. Sparano is the lead investigator for the clinical trial, called TAILORx (an acronym for Trial Assigning Individualized Options for Treatment). The study, sponsored by the National Cancer Institute, will enroll about 10,000 women with breast cancer at more than 900 institutions throughout the United States and Canada.

Breast cancer is the most frequently diagnosed cancer in women, with an estimated 235,000 new cases of invasive breast cancer expected in the United States and Canada in 2006. Nearly 140,000 of these women will have estrogen receptor-positive breast cancer that has not yet spread to the lymph nodes. The standard treatment is surgery to remove the tumor, plus radiation and hormonal therapy, which cures about 80 to 85 percent of patients. Adding chemotherapy can further reduce the risk of recurrence by about 25 percent, but it benefits only a small proportion of women.

Currently, most women with early-stage breast cancer are advised to undergo chemotherapy, yet it’s not clear that chemotherapy is worthwhile or even necessary in all these cases,” Dr. Sparano said.

The researchers will use OncotypeDXTM, a modern diagnostic test developed by Genomic Health, Inc., in Redwood, Calif., in collaboration with the National Surgical Adjuvant Breast and Bowel Project, a network of cancer research professionals. The test identifies which of 21 specific genes are turned on or off in the tumor. This genetic assessment estimates a patient’s risk of recurrence more precisely than standard clinical characteristics, such as tumor size and grade. It also helps predict whether a patient will benefit from chemotherapy.

“This test yields what is called a recurrence score. For about 55 percent of women, the recurrence score is greater than 25 or less than 11. In these cases, the test clearly indicates the most effective therapy: a combination of chemotherapy and hormones for women with high scores, and hormones alone for women with low scores,” Dr. Sparano said. “But about 45 percent of women receive scores that range from 11 to 25, where the treatment path is not so clear. Our study is designed to resolve this uncertainty.”

Women participating in the TAILORx trial will be assigned to one of three groups depending on their recurrence score. If the score is more than 25, women will receive chemotherapy plus hormonal therapy, the current standard of care. If it is less than 11, they will receive hormonal therapy alone. If the recurrence score is between 11 and 25, women will be randomized to receive either hormonal therapy or hormonal therapy together with chemotherapy.

“With this trial, we’re taking a big leap forward in integrating modern molecular diagnostic testing into clinical decision-making in order to individualize cancer treatments,” Dr. Sparano said.

Montefiore Medical Center, The University Hospital and Academic Medical Center for the Albert Einstein College of Medicine, ranks among the top one percent of all US hospitals based on its investments in medical innovation and cutting-edge technology. Montefiore invests more in order to enable compassionate, personalized care and the most positive outcomes for patients and their families in New York, the tri-state area and beyond.

Montefiore’s leadership in defining ‘state-of-the-art’ technology and ‘state-of-the-heart’ medical and nursing care in a teaching and research environment provides patients with access to world-class medical experts, the newest and most innovative treatments and the best medical center experience anywhere.

This 1,062-bed medical center includes the Henry and Lucy Moses Division, the Jack D. Weiler Hospital and The Children’s Hospital at Montefiore, a large home healthcare agency and a 21-site medical group practice located throughout the Bronx and nearby Westchester.

Montefiore treats all major illnesses and has distinguished centers of excellence in cardiology and cardiac surgery, cancer care, tissue and organ transplantation, children’s health, women’s health, surgery and the surgical subspecialties. Montefiore Medical Center focuses on providing family-centered healthcare in a nurturing environment that extends well beyond its hospital and ambulatory settings.

Axel F. Bang PR & Marketing

RELATED STORIES:
Extreme weight gain raises risk for recurrence among breast cancer survivors   3-D doppler ultrasound helps identify breast cancer   Antidepressant doesn’t raise breast cancer risk   Breast cancer tumor growth estimated through mammography screening data   Breast cancer vaccine helps body fight tumors   Breast cancer incidence is lower for Latinas   Early-Stage Breast Cancer Patients Lack Knowledge About Their Disease and May Not Receive the Treatment They Prefer   Social isolation ups risk of breast cancer death   COX-2 blockers may curb breast cancer risk   Linchpin Gene May Be Useful Target For Breast Cancer Therapies   Adding breast exam to mammogram - is it worth it?   Scientists identify avoidable breast cancer risk factors   Obesity linked with poorer breast cancer outcomes   Strong exercise may cut breast cancer risk   Women with Both Triple Negative Breast Cancer and BRCA Mutations Have Lower Risk of Recurrence   Dense breasts linked to return of breast cancer   Lack of social interaction affects health outcomes of breast cancer   Racial disparities seen in male breast cancer survival   Roche breast cancer pill fails to help older women   Adjuvant hormonal therapy reduces contralateral breast cancer risk   Hair Stylists Promote Breast Cancer Prevention Messages to Clients   Why are African Americans less Likely to Survive Certain Cancers?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]